Table 2.
Cox proportional hazards analysis of predictors of time to spontaneous HCV clearance among participants with acute HCV infection (n=632).
| Clearance Rate (/100 pyo) | Unadjusted HR (95% CI) | P | P overall | Model 1 Adjusted for age HR¥ (95% CI) | P | Model 2 Adjusted for age and site HR‡ (95% CI) | P | |
|---|---|---|---|---|---|---|---|---|
| Site | ||||||||
| UFO | 21.3 | 1.00 | - | 0.313 | - | - | - | - |
| ATAHC | 26.5 | 0.89 (0.53, 1.49) | 0.645 | - | - | - | - | - |
| BAHSTION | 33.8 | 1.23 (0.65, 2.31) | 0.527 | - | - | - | - | - |
| BBAASH | 21.4 | 1.19 (0.75, 1.90) | 0.464 | - | - | - | - | - |
| HEPCO | 18.2 | 0.80 (0.44, 1.47) | 0.476 | - | - | - | - | - |
| HIT-c | 48.7 | 1.51 (0.46, 4.94) | 0.497 | - | - | - | - | - |
| HIT-p | 11.2 | 0.63 (0.35, 1.13) | 0.123 | - | - | - | - | - |
| N2 | 14.4 | 0.75 (0.26, 2.13) | 0.589 | - | - | - | - | - |
| ACS | 21.1 | 1.36 (0.77, 2.39) | 0.289 | - | - | - | - | - |
| Age categorized* | ||||||||
| <30 years | 23.3 | 1.00 | - | 0.185 | 1.00 | - | 1.00 | - |
| 30–39 years | 20.0 | 0.86 (0.57, 1.29) | 0.456 | - | 0.99 (0.61, 1.62) | 0.976† | 1.05 (0.63, 1.74) | 0.862†† |
| ≥40 years | 14.8 | 0.61 (0.35, 1.06) | 0.077 | - | 0.80 (0.41, 1.57) | 0.522 | 0.84 (0.42, 1.69) | 0.630 |
| Female sex (vs. male sex) | 34.3 | 2.03 (1.51, 2.74) | <0.001 | - | 2.16 (1.48, 3.18) | <0.001 | 2.11 (1.43, 3.10) | <0.001 |
| Symptomatic HCV infection* | ||||||||
| No | 11.5 | 1.00 | - | 0.007 | - | - | - | - |
| Yes | 32.5 | 2.48 (1.36, 4.52) | 0.003 | - | - | - | - | - |
| Unknown | 20.0 | 2.29 (1.34, 3.92) | 0.003 | - | - | - | - | - |
| Ethnicity | ||||||||
| Caucasian | 20.8 | 1.00 | - | 0.763 | - | - | - | - |
| Aboriginal | 20.4 | 1.11 (0.58, 2.10) | 0.760 | - | - | - | - | - |
| Asian | 21.7 | 0.90 (0.29, 2.82) | 0.852 | - | - | - | - | - |
| Black | 9.8 | 0.54 (0.20, 1.47) | 0.231 | - | - | - | - | - |
| Other | 22.5 | 1.13 (0.67, 1.93) | 0.643 | - | - | - | - | - |
| IL28B CC genotype (vs. CT/TT) | 29.5 | 1.90 (1.38, 2.62) | <0.001 | - | 2.26 (1.52, 3.34) | <0.001 | 2.20 (1.48, 3.26) | <0.001 |
| HIV infection (vs. no HIV infection) | 23.1 | 0.88 (0.41, 1.88) | 0.744 | - | - | - | - | - |
| HCV genotype 1 (vs. genotype non-1)£,ρ | 18.1 | 1.49 (1.03, 2.16) | 0.035 | - | 1.56 (1.06, 2.30) | 0.025 | 1.44 (0.97, 2.14) | 0.074 |
At the time of incident HCV infection,
includes 448 participants in the final adjusted model,
overall P=0.813,
overall P=0.856,
includes 448 participants in the final adjusted model and is adjusted for site using a random-effects model including a frailty term to adjust for site,
among those with available genotypes.
pyo, person-years observation, UFO, UFO STUDY; ATAHC, Australian Trial in Acute Hepatitis C; BAHSTION, Boston Acute HCV Study: Transmission, Immunity and Outcomes Network; BBAASH, Baltimore Before and After Acute Study of Hepatitis; HEPCO, St. Luc Cohort, HEPCO; HITS-c, Hepatitis C Incidence and Transmission Study-Community; HITS-p, Hepatitis C Incidence and Transmission Study-Prison; N2, Networks 2; ACS, Amsterdam Cohort Studies.
HCV genotype 2 (vs 1; HR 0.84; 95%CI, 0.39, 1.82), HCV genotype 3 (vs 1; HR 0.68; 95%CI, 0.45, 1.02), HCV genotype 4 (vs 1; HR 0.41; 95%CI, 0.06, 2.98), mixed HCV genotype (vs 1; HR 0.57; 95%CI, 0.14, 2.32), unknown genotype (vs. 1; HR 3.40, 95%CI, 2.38, 4.87).